Kennedy Ferruggia, Associate Editor

RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.

Kristen Hartzell, PharmD, explains that long-term care pharmacies can counter vaccine fatigue and raise influenza vaccination rates among older adults.

Treated patients also had fewer postacute hospitalizations and deaths, but individuals without risk factors saw no benefit.

Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.

CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.

VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.

Pharmacists can reduce COVID-19 vaccine hesitancy through honest, nonjudgmental communication and by using every patient touchpoint as an opportunity to offer vaccination.

A study author explains how pharmacists can help close vaccination gaps in rural communities and what lower ICU admission rates among vaccinated older adults may mean.

Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.

Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.

Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.

Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.

In part 3 of this interview, Michael Mina, MD, PhD, discusses VYD2311’s variant-resistant design and the role pharmacists may play in explaining emerging immunization options.

The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.

VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.

In part 2 of this interview, Michael Mina, MD, PhD, discusses LIBERTY study data showing that VYD2311 boosted neutralizing activity without interfering with mRNA COVID-19 vaccine response.

Michael Mina, MD, PhD, discusses phase 3 LIBERTY study data showing that the monoclonal antibody VYD2311, alone or combined with an mRNA COVID-19 vaccine, was associated with fewer adverse events than vaccination alone.

Age is the leading factor in influenza vaccine selection, and vaccination remains effective well beyond the ideal September-to-October window.

Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.

A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.

American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.

Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.

Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.

Marie-Claire Seeley, PhD, MNurs, RN, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.

Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.

A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.

The all-oral combination is supported by phase 3 LITESPARK-011 data showing improved progression-free survival compared with cabozantinib.

Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.

Increasingly, pharmacists are leading the obesity management team.

A new device and expanded label tie LDL-C lowering to reduced cardiovascular risk.